Navigation Links
Watson Pharmaceuticals Reports Second Quarter 2008 Results
Date:8/6/2008

Total Net Revenue of $623 Million; GAAP EPS $0.53; Adjusted EPS $0.48

CORONA, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2008.

Second Quarter 2008 Results

Net revenue for the second quarter 2008 was $622.6 million and net income was $60.3 million, or $0.53 per diluted share. Net income for the second quarter 2008 included a gain related to a milestone payment and charges related to the Company's Global Supply Chain Initiative. Excluding special items as detailed in the reconciliation table below, adjusted net income for the second quarter was $54.6 million, or $0.48 per diluted share. Adjusted EBITDA for the second quarter 2008 was $137.5 million and cash flow from operations was $99.6 million. Cash and marketable securities were $278.2 million as of June 30, 2008.

"We are pleased with the financial results we delivered this quarter, driven by a strong performance in our Brand division which posted more than $100 million in product sales, a first in recent years," stated Paul Bisaro, Watson's President and Chief Executive Officer. "Our pipeline products oxybutynin topical gel for overactive bladder and silodosin for BPH were well received at data presentations at the recent American Urological Association meeting. Additionally, the FDA accepted our New Drug Application for our topical oxybutynin gel product and we successfully launched MixJect(TM), our new delivery system for Trelstar(R)."

"We continue to make progress on our near and long term strategic goals in the Generics Division, as evidenced by the recent product approvals and launches out of our
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Watson Receives FDA Approval for Generic Accuneb(R)
3. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
4. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
6. Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement
7. Watson Files FDA Application for Generic LYBREL(R)
8. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
9. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014  Four-dimensional (4-D) printing develops materials that ... stimuli such as changes in temperature. This advanced ... in multiple industries.  In the near future, 4-D ... objects ranging from human organs to parts used ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... 21, 2014 On Wednesday of last week ... use Redox Signaling molecules, became available for purchase in Australia ... "The way that RENU 28 works is, if you think ... of the rate of cellular renewal within your body. If ... of that rate of cellular renewal. What RENU 28 does ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, ... host a conference call to provide an update ... p.m. Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and ... Live web cast: www.neurotropebioscience.com , under "Investor Relations"The ... after completion through September 2, 2014 at (888) ...
(Date:8/20/2014)... Not long ago, it was more or less ... in the development cycle – even after the final ... that, like many things GxP, expectations for early E&L ... drug sponsors have been required by authorities to provide ... I/II. It’s not only clinical trial material containers causing ...
Breaking Biology Technology:Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... 14 For 88 percent of,companies, front-line and ... cover a variety of development skills but focus,strongly ... Yet only half of executive-level sales leaders ... leadership development and,training, according to a member-driven research ...
... April 14 eResearchTechnology,Inc. (eRT), (Nasdaq: ... today their,alliance to provide integrated Cardiac Safety ... worldwide., eResearchTechnology is a leading provider ... other services,to the pharmaceutical, biotechnology, medical device, ...
... Corporation,(Pink Sheets: PHCP) (the "Company") clarified today that ... connection with,market transactions and are a valid representation ... This clarification was issued in response to,information from ... firms,will not negotiate Phlo common stock certificates issued ...
Cached Biology Technology:Developing Sales Leaders: Benchmarks Reveal Tactics that Will Propel Your Business 2eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services 2eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services 3Phlo Clarifies That Pre-Reverse Split Certificates Are Negotiable in Market Transactions 2
(Date:8/21/2014)... 2014 , WHERE: , San Diego Convention ... 92101 , WHAT: , Invited and platform ... research in human genetics. Examples of sessions include: ... rare genetic variants in health and disease, the ... sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , Crowdsourced ...
(Date:8/21/2014)... from North Carolina State University have developed a novel ... model has applications for creating new materials as well ... "Our new technique allows us to model much larger ... much more quickly," says Nan Li, lead author of ... in NC State,s Department of Materials Science and Engineering. ...
(Date:8/20/2014)... Knoxville, research finds life can persist in a cold, ... of a team that examined waters and sediments from ... and found the extreme environment supports microbial ecosystems. ... and her colleagues has implications for life in other ... system. The findings are published in the current edition ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... are thrown away in the European Union each year. However, ... The brown skin and external layers are rich in fibre ... fructans. All of these substances are beneficial to health. ... line with the growing demand for these bulbs. More than ...
... A recent multi-center study determined that women with ... seizures during anovulatory cyclesmenstrual cycles where an egg is ... the study publishing today in Epilepsia , a ... steroids may play a role in GTCS occurrence. ...
... (UPC) have developed a method for evaluating the vulnerability ... method, which has been applied on the Catalan coastline, ... high rate of vulnerability to flooding, while 20% are ... no tool for evaluating coastal storm vulnerability that could ...
Cached Biology News:Dry onion skin has a use 2Greater seizure frequency seen in women with epilepsy during anovulatory cycle 2One-third of central Catalan coast is very vulnerable to storm impact 2
Bag-1 (K-20)...
... contains 4 deuterium atoms at the 3, ... intended for use as an internal standard ... by GC- or LC-mass spectrometry. PGE2 is ... arachidonic acid and one of the most ...
Deletions, insertions or substitutions. Mutations in plasmids of size up to 15 kb. Single or multiple mutations...
Request Info...
Biology Products: